Ocugen pays $15 mn upfront to Bharat Biotech for Covaxin rights in Canada
The Hindu
Similar to the US arrangement, Ocugen will retain 45 per cent of the profit from sales of Covaxin in Canada.
Ocugen Inc, the US partner for has announced the payment of $15 million upfront to the Indian drug maker for extending the vaccine rights to Canada. Ocugen in a regulatory filing said it has agreed to pay another $10 million to Bharat Biotech within a month from the commercial launch of Covaxin in the North American country. Also read:
Gold and silver futures soar to record highs amid U.S. Fed probe and escalating geopolitical tensions, driving investors to safe havens.
OpenAI and SoftBank Group will invest $500 million each in SB Energy to expand data centre and power infrastructure for their Stargate initiative
Sensex drops 455 points amid foreign fund outflows and trade concerns, reflecting a cautious market sentiment.
Elon Musk’s X Corp sued 18 major music publishers and a leading U.S. music industry trade association on Friday
Four banks, Bank of Baroda, RBL Bank, Yes Bank, and State Bank of India, challenge RBI's decision to disclose NPAs and defaulters' list under RTI, citing potential harm to commercial interests.
Adani Group plans a ₹1.5 lakh crore investment in Kutch, focusing on renewable energy, ports, and logistics over five years.
Mukesh Ambani announces ₹7 lakh crore investment in Gujarat, emphasizing clean energy, AI, and support for Olympic ambitions.
India mandates selfies and 'penny drop' for crypto KYC, discouraging ICOs and ensuring strict anti-money laundering measures.
Mukesh Ambani announces ₹7 lakh crore investment in Gujarat, emphasizing clean energy, AI, and support for Olympic ambitions.
The All India Cashew Association calls for urgent action against illegal cashew imports threatening India's domestic processing industry.
Moody’s upgrades Shriram Finance’s outlook to positive, citing strategic benefits from MUFG Bank's upcoming investment and improved financial stability.
India's rice exports soar to near record levels in 2025, driven by lifted curbs and increased global demand.
Dr. Reddy's responds to U.S. FDA queries regarding its Hyderabad biologics facility following a recent inspection.